CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU ApprovalZacks Investment Research • 12/15/25
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?Zacks Investment Research • 12/12/25
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight lossGlobeNewsWire • 12/12/25
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, LillyCNBC • 12/11/25
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?Zacks Investment Research • 12/10/25
This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock?The Motley Fool • 12/05/25
Wegovy's prices are going down, but they are ‘wildly different' — and confusingMarket Watch • 12/04/25
Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatmentReuters • 12/04/25